Recent Updates — TELA
TELA Bio, Inc. held a Special Meeting of Stockholders on October 8, 2026, where shareholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split with a ratio between one-for-five and one-for-fifteen. The Board retains sole discretion to set the exact ratio within this range. This approval follows receipt of a letter from Nasdaq on October 5, 2026, confirming that TELA Bio has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. Consequently, the company does not intend to effect an immediate reverse stock split at this time. The vote was decisive, with approximately 30.5 million shares voting in favor against roughly 80,000 votes against. TELA Bio develops and commercializes medical devices for wound care and surgical applications.
TELA Bio, Inc. received a letter from The Nasdaq Stock Market LLC confirming that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). The matter regarding non-compliance is now closed, and the company's common stock continues to be listed and traded on the exchange under the symbol "TELA". TELA Bio, Inc. operates in the medical device industry, developing wound care products.
TELA Bio, Inc. announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh device designed for soft tissue reinforcement. This regulatory milestone marks the first implant to be fully developed in the company’s ISO 8 certified cleanroom in Malvern, Pennsylvania, and expands TELA Bio's portfolio of innovative soft-tissue reconstruction solutions. The clearance enables the commercial-stage medical technology company to broaden its footprint in the market by offering a new option for surgeons and patients that leverages natural healing responses while minimizing long-term exposure to permanent synthetic materials.
TELA Bio, Inc. entered into a Limited Consent to Credit Agreement with Perceptive Credit Holdings V, LP on September 28, 2026. The consenting lenders agreed that the minimum Revenue covenant under the existing Credit Agreement dated November 13, 2025, shall not be tested for fiscal quarters ending approximately September 30, 2026, and December 31, 2026. This waiver allows the company to bypass specific financial performance requirements during these periods. TELA Bio operates in the medical device industry, specializing in wound care solutions.
TELA Bio, Inc. received notification from Nasdaq on September 15, 2026, that its common stock is subject to delisting because the minimum bid price remained below $1.00 for 30 consecutive business days and the company failed to regain compliance within the 180-day grace period. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the outcome. To address the deficiency, TELA Bio filed a proxy statement on September 14, 2026, seeking shareholder approval for a reverse stock split with a ratio ranging from 1-for-5 to 1-for-15 at a special meeting scheduled for October 8, 2026. The company operates in the medical device industry, specializing in wound care and tissue regeneration technologies.
TELA Bio announced a strategic cost reduction initiative to preserve capital and extend its cash runway into 2028. The company is reducing its workforce by approximately 20%, from 201 to 160 full-time employees, aiming to lower annual operating expenses by $17.0 million. This restructuring involves a one-time charge of approximately $1.5 million for severance and related costs, expected to be substantially completed in the third quarter of 2026. Concurrently, Roberto Cuca stepped down as Chief Financial Officer and Chief Operating Officer effective August 31, 2026, due to termination without cause under his employment agreement. Heather Getz was appointed as the new principal financial officer. TELA Bio operates in the medical technology industry, providing soft-tissue reconstruction solutions.